Clinical Journal of Gastroenterology, Год журнала: 2024, Номер 17(3), С. 451 - 456
Опубликована: Фев. 23, 2024
Язык: Английский
Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 204, С. 104497 - 104497
Опубликована: Сен. 7, 2024
Язык: Английский
Процитировано
5
Journal of Oncology Pharmacy Practice, Год журнала: 2024, Номер 30(8), С. 1411 - 1431
Опубликована: Июль 26, 2024
Dostarlimab, a humanized monoclonal PD-1 blocking antibody, is being tested as cancer therapy in this review. Specifically, it addresses mismatch repair failure endometrial and locally progressed rectal patients.
Язык: Английский
Процитировано
4
Frontiers in Oncology, Год журнала: 2025, Номер 14
Опубликована: Янв. 13, 2025
Background Ferroptosis is a cell death mode caused by excessive accumulation of lipid peroxides disturbance intracellular metabolic pathway, which closely related to iron and cholesterol metabolism homeostasis. Its regulation within the hypoxic tumor microenvironment (TME) has potential improve effectiveness immunotherapy. The predictive role ferroptosis in gastric cancer (GC) hypoxia TME, particularly relation TME immune infiltration, not been fully explained. Methods By analyzing mRNA expression data hypoxia-related genes, prediction model was constructed evaluate further value clinical characteristics, immunotherapy efficacy cancer, essential genes were validated. Results Two distinct molecular states ferroptosis-hypoxia identified GC. Notably, patients with high risk scores (FHRS) displayed significant levels epithelial-mesenchymal transition (EMT), associated unfavorable prognosis, increased chemoresistance, heightened immunosuppression. Conclusions This study demonstrates that under conditions significantly affects modulation microenvironment. FHRS can independently predict prognosis cancer. Assessing status individual will help selecting more suitable regimens providing better understanding characteristics predicting immunotherapeutic outcomes.
Язык: Английский
Процитировано
0
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Фев. 5, 2025
Microsatellite instability (MSI) is a widely studied molecular signature, which associated with long-term benefit in patients treated immune checkpoint inhibitor therapy. This approach has been proven to be effective the treatment of MSI-positive colorectal cancer (CRC). Analysis serial liquid biopsy samples allows detect changes tumor response Typically, somatic mutations are used for tracing dynamics tumor, and assessment DNA signatures such as MSI not currently these purposes. Here, we describe case CRC, who received nivolumab monotherapy. Sequential sampling patient’s plasma demonstrated an increase burden (bMSI), was found correlate driver mutation one month after starting nivolumab, hyperprogressive disease. Thus, analysis bMSI via NGS may promising method timely effectiveness by CRC.
Язык: Английский
Процитировано
0
Modern Pathology, Год журнала: 2025, Номер unknown, С. 100752 - 100752
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(6), С. 2522 - 2522
Опубликована: Март 11, 2025
The treatment landscape of metastatic colorectal cancer (mCRC) has undergone significant evolution, with the introduction targeted therapies and immunotherapy dramatically altering management microsatellite instability-high (MSI-H) tumors. However, majority patients, particularly those microsatellite-stable (MSS) disease, remain refractory to immunotherapy, necessitating exploration alternative therapeutic strategies. This review summarizes current options for heavily pretreated mCRC patients who are not eligible or clinical trials. Approved mCRC, including regorafenib, trifluridine/tipiracil (FTD/TPI), fruquintinib, demonstrate modest survival benefits but often associated toxicities. Additionally, innovative approaches targeting specific mutations such as KRAS G12C, HER2 amplification, BRAF V600E discussed, highlighting emerging combination regimens immune checkpoint inhibitors other agents overcome resistance mechanisms. potential rechallenge strategies using previously administered therapies, oxaliplatin anti-EGFR agents, is examined, supported by retrospective prospective studies. Furthermore, role older drugs like mitomycin C in capecitabine revisited, offering insights into their viability advanced settings. Ongoing trials novel combinations expected provide further clarity on optimizing sequential personalizing therapy patients. emphasizes need comprehensive molecular profiling shared decision-making improve outcomes quality life this challenging patient population.
Язык: Английский
Процитировано
0
World Journal of Gastrointestinal Oncology, Год журнала: 2025, Номер 17(4)
Опубликована: Март 24, 2025
Although targeted therapy provides survival benefits for patients with metastatic colorectal cancer, some develop resistance to these treatments. Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of cancer and has been established as therapeutic target. This case report describes Chinese patient HER2-amplified advanced rectal who showed no response chemotherapy therapies against vascular endothelial but achieved remarkable following treatment immune checkpoint inhibitors (ICIs) combination pyrotinib. The oxaliplatin ICIs pyrotinib demonstrates synergistic effects after late-stage disease progression. may be effective treating cancer. Chemotherapy progression could enhance efficacy synergistically.
Язык: Английский
Процитировано
0
Cancer Cell, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 186, С. 118014 - 118014
Опубликована: Март 31, 2025
Язык: Английский
Процитировано
0
Nature Reviews Clinical Oncology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 3, 2025
Язык: Английский
Процитировано
0